Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Session VI: Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials

Identification of immunogenic markers in pancreatic and ovarian cancer by seromics

Sacha Gnjatic
Sacha Gnjatic
Ludwig Institute for Cancer Research at Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Protein arrays offer a miniaturized platform that can be used to determine specific reactivity of serum or plasma samples against very large sets of antigens, a process that can be referred to as seromics. We first validated the technology in comparison to ELISA-based assays using sera with previously determined specificity to antigens present on microarrays. We also defined a set of stringent normalization and calculation strategies tailored to the challenges posed by the use of serum for antigen detection: high variability between individuals in reactivity and serum composition, large range of titers expected to individual antigens with variable frequency, etc.

A set of 60 sera from pancreatic patients and 52 sera from ovarian cancer patients were selected according to disease status (localized vs. metastatic) and outcome (long-term vs. short-term survival), and compared to a set of 53 sera from age-matched healthy donors. Data were analyzed according to algorithms dedicated to this type of analyses.

We describe here the results of these analyses, which yielded a series of antigens capable of eliciting immune responses with higher frequency and specificity in the sera of cancer patients in comparison to normal subjects. We compare the frequency of these immunogenic antigens in pancreatic vs. ovarian cancer, define shared targets, and their relationship to clinical status. Together, these data highlight the potential for the discovery of new immunogenic targets in cancer with immunotherapeutic potential for vaccine development, but also for the definition of biomarker signatures able to diagnose cancer status, with possible predictive value. We finally applied these discoveries to determine their use as predictive tools during response to immunotherapeutic intervention, such as the manipulation of immunomodulatory pathways during CTLA-4 blockade.

Collaborative study with: Dirk Jäger, Markus Büchler, and Benedikt Brors from the German Cancer Research Center, Heidelberg, Germany; Kunle Odunsi from Roswell Park Cancer Institute, Buffalo, NY; Nasser Altorki from Weill Medical College of Cornell University, New York, NY; Jim Allison and Jedd Wolchok, Memorial Sloan-Kettering Cancer Center, New York, NY; Colin Wheeler and Rachel Fallon, Sense Proteomics, Maidenhead, UK; Gerd Ritter, Erika Ritter, Lloyd Old, Ludwig Institute for Cancer Research, New York, NY.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Sacha Gnjatic
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 2)
January 2008
Volume 8, Issue Suppl 2
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of immunogenic markers in pancreatic and ovarian cancer by seromics
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Identification of immunogenic markers in pancreatic and ovarian cancer by seromics
Sacha Gnjatic
Cancer Immun January 1 2008 (8) (Suppl 2) 23;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Identification of immunogenic markers in pancreatic and ovarian cancer by seromics
Sacha Gnjatic
Cancer Immun January 1 2008 (8) (Suppl 2) 23;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Identification of antibody responses induced in patients with biochemically recurrent and castration-resistant prostate cancer receiving GVAX immunotherapy for prostate cancer
  • Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment
  • Harmonized T cell monitoring assays as biomarkers for immunotherapy trials: A data driven approach by the CIMT Immunoguiding Program ("CIP")
Show more Session VI: Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement